Immune check-point in endometrial cancer

被引：35
|
作者：
De Felice, Francesca [1 ]
Marchetti, Claudia [2 ]
Tombolini, Vincenzo [1 ]
Panici, P. Benedetti [3 ]
机构：
[1] Sapienza Univ Rome, Policlin Umberto 1, Dept Radiotherapy, Viale Regina Elena 326, I-00161 Rome, Italy
[2] Fdn Policlin Univ A Gemelli IRCCS, Div Gynecol Oncol, Rome, Italy
[3] Sapienza Univ Rome, Dept Gynecol Obstet Sci & Urol Sci, Rome, Italy
来源：
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 24卷 / 08期
关键词：
Endometrial cancer; Immunotherapy; Immune check-point; Survival; Microsatellite instability; Mismatch repair; MISMATCH REPAIR STATUS; WOMEN; BLOCKADE; TUMORS; PEMBROLIZUMAB; ASSOCIATION; CARCINOMAS; EXPRESSION; OUTCOMES; PD-1;
D O I：
10.1007/s10147-019-01437-7
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Background Endometrial cancer (EC) is one of the most frequent tumors in women. Despite recent advances in treatment approaches, the prognosis in advanced, recurrent, or metastatic disease remains poor. The aim was to provide the clinician with an update, the current status, and the new developments in the management of EC. Based on the new EC molecular classification, we focused on the impact of immune check-point inhibitors. Methods Pivotal trials, published literature, and conference proceedings were reviewed. PubMed and Scopus databases were searched to select English-language articles. Results Immune check-point inhibitors are the subject of ongoing studies and their benefit seems to be related to microsatellite instability (MSI) status. Conclusions Immune check-point inhibitors should be considered a promising treatment option to better personalize therapeutic strategies in EC.
引用
收藏
页码：910 / 916
页数：7
相关论文
共 50 条
  • [31] Cisplatin increases PD-L1 expression and optimizes immune check-point blockade in non-small cell lung cancer
    Fournel, Ludovic
    Wu, Zherui
    Stadler, Nicolas
    Damotte, Diane
    Lococo, Filippo
    Boulle, Geoffroy
    Segal-Bendirdjian, Evelyne
    Bobbio, Antonio
    Icard, Philippe
    Tredaniel, Jean
    Alifano, Marco
    Forgez, Patricia
    CANCER LETTERS, 2019, 464 : 5 - 14
  • [32] Blood-based prognostic scores and early dynamics under immunotherapy to select patients with metastatic solid tumors for continuing immune check-point inhibition: a prospective longitudinal study
    Garcia-Corbacho, Javier
    Indacochea, Alberto
    Victoria, Ivan
    Moreno, Debora
    Angelats, Laura
    Gonzalez Navarro, Azucena E.
    Mezquita, Laura
    Braso-Maristany, Fara
    Galvan, Patricia
    Mellado, Begona
    Vinolas, Nuria
    Sauri, Tamara
    Nogue, Miquel
    Adamo, Barbara
    Maurel, Joan
    Pineda, Estela
    Gaba, Lydia
    Reig, Oscar
    Baste, Neus
    Sanfeliu, Esther
    Juan, Manel
    Prat, Aleix
    Schettini, Francesco
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2025, 74 (03)
  • [33] Pulmonary toxicities of immune check point inhibitors in the management of cancer: mini review
    Jayakrishnan, B.
    Al-Moundhri, Mansour
    Burney, Ikram
    Al-Hashami, Zamzam
    Al-Bimani, Khalid
    ADVANCES IN RESPIRATORY MEDICINE, 2022, 90 (03) : 219 - 229
  • [34] Mismatch repair gene MSH6 correlates with the prognosis, immune status and immune checkpoint inhibitors response of endometrial cancer
    Zhou, Lin-Zhi
    Xiao, Hong-Qi
    Chen, Jie
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [35] Immune Checkpoint Inhibitors (ICI) in Advanced and Recurrent Endometrial Cancer
    Bose, Chinmoy K.
    INDIAN JOURNAL OF GYNECOLOGIC ONCOLOGY, 2022, 20 (01)
  • [36] Immune check-point inhibitor-related pneumonitis: acute lung injury with rapid progression and organising pneumonia with less severe clinical disease
    Imran, Saira
    Golden, Andrew
    Feinstein, Marc
    Plodkowski, Andrew
    Bodd, Francis
    Rekhtman, Natasha
    Travis, William D.
    Stover, Diane E.
    Sauter, Jennifer L.
    HISTOPATHOLOGY, 2022, 81 (06) : 724 - 731
  • [37] The role of an immune signature for prognosis and immunotherapy response in endometrial cancer
    Meng, Yue
    Yang, Yuebo
    Zhang, Yu
    Yang, Xiaohui
    Li, Xiaomao
    Hu, Chuan
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2021, 13 (02): : 532 - 548
  • [38] The gut microbiome, immune check point inhibition and immune-related adverse events in non-small cell lung cancer
    Bredin, Philip
    Naidoo, Jarushka
    CANCER AND METASTASIS REVIEWS, 2022, 41 (02) : 347 - 366
  • [39] Bevacizumab for stereotactic radiosurgery-induced radiation necrosis in patients with non-small cell lung cancer treated with immune check-point inhibitors
    Moore, Assaf
    Yust-Katz, Shlomit
    Icht, Oded
    Eliyahou, Ruth
    Gordon, Noa
    Cohen, Aharon Yehonatan
    Goldstein, Iris Magdalena
    Peled, Nir
    Seigal, Tali
    Amiel, Alexandra
    Dudnik, Elizabeth
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2021, 427
  • [40] Mifepristone Extends Both Length and Quality of Life in a Patient With Advanced Non-small Cell Lung Cancer that Has Progressed Despite Chemotherapy and a Check-point Inhibitor
    Check, Jerome H.
    Check, Diane
    Poretta, Trina
    ANTICANCER RESEARCH, 2019, 39 (04) : 1923 - 1926
12345